Pacira Pharmaceuticals, Inc. Release: New Data Demonstrate Reduction in Opioid Use, Hospital Cost and Length of Stay With EXPAREL as the Foundation of a Multimodal Regimen

Published: Nov 20, 2012

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that results from the first IMPROVE study to complete its prospective Phase 4 clinical program were published in the online version of the Journal of Pain Research. The IMPROVE studies compare the difference in opioid use, total hospital cost and length of stay (LOS) between patients receiving EXPAREL® (bupivacaine liposome injectable suspension) as the foundation of an opioid-sparing multimodal regimen versus a standard opioid-based postsurgical pain management regimen.

Back to news